CompletedNCT04995029
Extended-release buprenorphine induction and maintenance dosing for high-risk opioid use
About this title
Read the official source — NCT04995029Medication studyAges 18+United States + CanadaAddiction
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Garden Grove and 28 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: October 26, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 785
- Sponsor
- Indivior Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, Canada
- Age range
- Over 18 Years
- Official registry ID
- NCT04995029
- Official title
Show the full official title
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Garden Grove, United States · Panorama City, United States · San Diego, United States
21 more locations
- Bay Pines, United States
- Gainesville, United States
- Lakeland, United States
- Miami Lakes, United States
- North Miami, United States
- Orlando, United States
- Boston, United States
- Berlin, United States
- Cherry Hill, United States
- New York, United States
- Durham, United States
- Monroe, United States
- Dayton, United States
- Oklahoma City, United States
- Altoona, United States
- Clinton, United States
- Greenville, United States
- Myrtle Beach, United States
- DeSoto, United States
- Bountiful, United States
- Toronto, Canada
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Indivior Inc.
Did this study involve medication?
Yes. The study involved medication, including Transmucosal Buprenorphine and Extended-release Buprenorphine.
Who was this study for?
Listed age limits: from 18 years.
